OLIPASS CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 545 KRW | +3.42% |
|
-3.54% | -29.59% |
| May. 29 | OLIPASS Corporation announced that it has received KRW 2.501 billion in funding | CI |
| Mar. 18 | OLIPASS Corporation announced that it has received KRW 3.5 billion in funding | CI |
| Sales 2021 | 852M 616K | Sales 2022 | 2.3B 1.66M | Capitalization | 188B 136M |
|---|---|---|---|---|---|
| Net income 2021 | -25.14B -18.17M | Net income 2022 | -24.17B -17.47M | EV / Sales 2021 | 295 x |
| Net cash position 2021 | 18.29B 13.22M | Net cash position 2022 | 6.2B 4.48M | EV / Sales 2022 | 79 x |
| P/E ratio 2021 |
-10.8
x | P/E ratio 2022 |
-7.66
x | Employees | 78 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 88.86% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.42% | ||
| 1 week | -3.54% | ||
| Current month | +6.65% | ||
| 1 month | +13.07% | ||
| 3 months | -11.38% | ||
| 6 months | -29.59% | ||
| Current year | -29.59% |
1 week
506.00
578.00
1 month
468.00699.00
Current year
421.00799.00
1 year
421.003 450.00
3 years
421.0015 800.00
5 years
421.0024 066.67
10 years
421.0024 066.67
| Managers | Title | Age | Since |
|---|---|---|---|
Shin Chung
FOU | Founder | 64 | 06-11-15 |
Young-Yup Park
DFI | Director of Finance/CFO | 46 | - |
Heung-Sik Yoon
CTO | Chief Tech/Sci/R&D Officer | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heung-Sik Yoon
CTO | Chief Tech/Sci/R&D Officer | 64 | - |
Shin Chung
FOU | Founder | 64 | 06-11-15 |
Se-Bin Oh
BRD | Director/Board Member | 74 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 545 | +3.42% | 337,765 |
| 24-07-01 | 527 | +3.13% | 110,729 |
| 24-06-28 | 511 | -0.39% | 136,886 |
| 24-06-27 | 513 | -5.00% | 275,052 |
| 24-06-26 | 540 | -4.42% | 571,441 |
End-of-day quote Korea S.E., July 01, 2024
More quotes
OliPass Corporation is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.59% | 13.7M | |
| +14.95% | 122B | |
| +15.91% | 113B | |
| +17.26% | 26.22B | |
| -24.33% | 19.01B | |
| -19.14% | 15.71B | |
| -18.36% | 15.22B | |
| -47.37% | 14.72B | |
| +58.52% | 14.58B | |
| +5.02% | 13.84B |
- Stock Market
- Equities
- A244460 Stock
